Cargando…
Transcriptomic profile of intrinsically chemoresistant acute myeloid leukemia patients
We recently identified three sub-populations of refractory acute myeloid leukemia (AML) patients with distinct intrinsic resistance mechanisms. Furthermore, we were able to risk-stratify the overall survival of the patients and identify patients who would likely benefit from alternative therapies.
Autor principal: | Horibata, Sachi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816412/ https://www.ncbi.nlm.nih.gov/pubmed/31692823 http://dx.doi.org/10.1080/23723556.2019.1650631 |
Ejemplares similares
-
Peripheral T-cell tolerance in hosts with acute myeloid leukemia
por: Chen, Xiufen, et al.
Publicado: (2013) -
Acute myeloid leukemia therapeutics: CARs in the driver’s seat
por: Mardiros, Armen, et al.
Publicado: (2013) -
Immunotherapy of acute myeloid leukemia based on γδ T cells
por: Gertner-Dardenne, Julie, et al.
Publicado: (2012) -
Interferon α may be back on track to treat acute myeloid leukemia
por: Smits, Evelien L.J.M., et al.
Publicado: (2013) -
Targeting cathepsin G in myeloid leukemia
por: Alatrash, Gheath
Publicado: (2013)